Working… Menu

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02749903
Recruitment Status : Active, not recruiting
First Posted : April 25, 2016
Last Update Posted : May 29, 2019
National Cancer Institute (NCI)
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : February 21, 2019
Study Completion Date : No date given